Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DMD drug developers stake out territory in rare disease market

This article was originally published in Scrip

Executive Summary

Parents of boys with Duchenne muscular dystrophy (DMD) have had little good news during the past few months due to setbacks for Prosensa and Sarepta Therapeutics, but three different biotechnology company presentations at the 32nd Annual JP Morgan Healthcare Conference offered signs of hope for therapies that may keep their sons from losing the ability to walk, eat and breathe on their own.

Advertisement

Related Content

DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC024162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel